Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

Nadine J. McCleary, MD, MPH

Medical Oncology

Make an Appointment
Watch Video

Nadine J. McCleary, MD, MPH


  • Senior Physician
  • Associate Professor of Medicine, Harvard Medical School


Clinical Interests

  • Gastrointestinal cancers
  • Geriatric oncology
  • Older patients with cancer

Contact Information

  • Appointments617-632-4500
  • Office Phone Number617-632-6729
  • Fax617-632-5370


Dr. Nadine Jackson McCleary earned a Bachelor of Science in Nursing from the University of Pennsylvania in 1998. She went on to earn both a Masters in Public Health (2002) and medical degree (2003) from Johns Hopkins University Bloomberg School of Public Health and School of Medicine, respectively. She completed residency in internal medicine at Johns Hopkins Hospital in 2006 and fellowship in clinical hematology and oncology at Dana-Farber/Partners CancerCare in 2009. Dr. McCleary joined the staff of Dana-Farber Cancer Institute and Brigham and Women’s Hospital in 2009 where she is a medical oncologist and clinical investigator. Her research is focused on improving health and treatment outcomes for older patients with cancer.

Board Certification:

  • Internal Medicine
  • Medical Oncology


  • Dana-Farber/Partners CancerCare, Medical Oncology


  • Johns Hopkins Hospital, Internal Medicine

Medical School:

  • Johns Hopkins Bloomberg School of Public Health
  • Johns Hopkins School of Medicine

Recent Awards:

  • Gloria Spivak Faculty Advancement Award 2012
  • National Comprehensive Cancer Network Young Investigator Award 2011
  • Gastrointestinal SPORE Career Development Award 2010
  • National Cancer Institute Training Grant: Program in Cancer Outcomes Research 2009
  • American Society of Clinical Oncology Merit Award 2009
  • Dana-Farber Cancer Institute Perry Levy Fellow Award 2008
  • American Society of Clinical Oncology/Hartford Foundation Young Investigator Award 2008


Health and treatment outcomes of older patients with gastrointestinal cancer
Prognostic/Predictive factors of survival for older patients with gastrointestinal cancer

Dr. McCleary’s overall career objective is to apply emerging scientific knowledge about cancer biology, epidemiology, geriatrics and pharmacology to treatment decisions that clinicians face every day. Her focus is on treatment decision making in the geriatric population where knowledge of tumor biology, drug efficacy, and host specific factors such as comorbidity, must be synthesized to facilitate informed choices. Her research objective is to develop an age-specific prognostic model for older adults with colorectal cancer. As a faculty member of Gastrointestinal Cancer Center at the Dana-Farber Cancer Institute, she divides her time between patient care and clinical investigation in geriatric oncology.

McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, O’Connell MJ, Twelves CJ, Saltz LB, Sargent DJ, Haller D. Impact of age on the efficacy of newer adjuvant therapies in 14,528 patients with stage II/III colon cancer: Findings from the ACCENT Database. J Clin Oncol. 2013 – in press


McCleary NJ, Odejide O, Szymonifka J, Ryan D, Hezel A, Meyerhardt JA.  Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. Clin Colorectal Cancer 2012 - in press


McCleary NJ, Wigler, D, Berry D, Sato K, Abrams T, Chan J, Enzinger P, Ng K, Wolpin B, Schrag D, Fuchs CS, Hurria A, Meyerhardt JA. Feasibility of computer-based self-administered cancer-specific geriatric assessment in older pts with gastrointestinal malignancy. Oncologist 2012 – in press


Jackson McCleary N, Niedzwiecki D, Hollis D, Saltz L, Mayer R, Schaefer P, Whittom R, Hantel A, Benson A, Goldberg R, Meyerhardt J. The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. Cancer. 2010 February 15; 116 (4): 957-966. PMID: 20052723. PMCID: PMC2884300.


Jackson McCleary N, Meyerhardt J. New developments in the adjuvant therapy of stage II colon cancer: Risk assessments in the older patient. Oncology. 2010 January; 24 (1).  PMID: 20225605.


Jackson N, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, Meyerhardt J. Comparing Safety and Efficacy of First-Line Irinotecan/Fluoropyrimidine Combinations in Elderly versus Nonelderly Patients with Metastatic Colorectal Cancer:  Findings from the BICC-C Study. Cancer. 2009 June 15; 115 (12): 2617-29. PMID: 19382200.



Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions